Want to see AU:EVE full AI Analyst Report?
EVE Health Group Limited (EVE) AI Stock Analysis
EVE Health Group Limited
(ASX:EVE)
The score is driven primarily by severe financial weakness, including ongoing losses, declining revenue, and persistent cash burn. Bearish technical trends and the negative P/E ratio provide little offsetting support. The weighted result is 37.75, rounded to 38.
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 4.58M
- Dividend Yield
- ―
- Average Volume (3M)
- 573.60K
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 0.21
- Revenue Growth
- -33.53%
- EPS Growth
- 42.98%
- Country
- Australia
- Employees
- 3
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
EVE Health Group Limited Business Overview & Revenue Model
Company Description
Based in Subiaco, Australia, Eve Health Group Limited, originally incorporated in 2003 as EVE Investments Limited, is an international provider of health, wellness, and nutritional products. The company operates across Australia, New Zealand, the Asi...
How the Company Makes Money
EVE primarily makes money by selling its branded health products, generating revenue from product sales through retail, pharmacy, and other distribution channels (including wholesale/distributor arrangements where applicable). Key revenue streams are...
EVE Health Group Limited Financial Statement Overview
Summary
Very weak performance: the provided income statement, balance sheet, and cash flow scores are 24, 40, and 20, respectively. Shrinking revenue, substantial losses, and persistent cash burn outweigh the benefit of debt elimination and recent asset recovery. The score is set at the minimum permitted level.
Income Statement
24NegativeBalance Sheet
40NegativeCash Flow
20Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.15M | 1.15M | 1.73M | 2.13M | 2.33M | 2.01M |
| Gross Profit | -106.51K | -106.51K | 824.03K | 876.96K | 827.83K | -1.00M |
| EBITDA | -1.77M | -1.77M | -1.43M | -1.51M | -2.18M | -4.53M |
| Net Income | -1.89M | -1.89M | -1.58M | -1.90M | -4.04M | -5.37M |
Balance Sheet | ||||||
| Total Assets | 4.28M | 4.28M | 4.12M | 2.52M | 4.13M | 8.07M |
| Cash, Cash Equivalents and Short-Term Investments | 1.24M | 1.24M | 903.42K | 106.17K | 192.48K | 1.10M |
| Total Debt | 0 | 0 | 91.28K | 74.85K | 4,282 | 492.39K |
| Total Liabilities | 330.02K | 330.02K | 572.45K | 1.30M | 1.01M | 1.14M |
| Stockholders Equity | 3.95M | 3.95M | 3.55M | 1.22M | 3.12M | 6.93M |
Cash Flow | ||||||
| Free Cash Flow | -1.74M | -1.74M | -1.62M | -1.11M | -1.65M | -3.80M |
| Operating Cash Flow | -1.74M | -1.74M | -1.62M | -1.11M | -1.65M | -3.77M |
| Investing Cash Flow | -1,898 | -1,898 | 2.13M | 874.27K | 498.46K | -26.05K |
| Financing Cash Flow | 2.08M | 2.08M | 279.09K | 146.37K | 240.69K | 1.74M |
EVE Health Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EVE, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.60 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EVE.
EVE Health Group Limited Peers Comparison
Overall Rating
AU:NUC46Neutral
AU:AHF45Neutral- AU:EVE38Underperform
AU:HCT29Underperform
AU:NGS26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| AU:NUC | 46Neutral | AUD 12.55M | -1.68 | -88.51% | ― | 11.96% | -81.99% |
| AU:AHF | 45Neutral | AUD 12.97M | -4.21 | -12.90% | ― | 0.46% | 46.48% |
| AU:EVE | 38Underperform | AUD 4.76M | -2.11 | -49.07% | ― | -33.53% | 42.98% |
| AU:HCT | 29Underperform | AUD 12.14M | -3.79 | 1795.70% | ― | 0.72% | -486.96% |
| AU:NGS | 26Underperform | AUD 18.32M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:EVE | EVE Health Group Limited | 0.01 | -0.02 | -56.67% | |
| AU:AHF | Australian Dairy Nutritionals Group | 0.02 | -0.02 | -54.29% | |
| AU:NUC | Nuchev Pty Ltd | 0.08 | -0.06 | -42.86% | |
| AU:HCT | Holista Colltech Limited | 0.03 | -0.04 | -57.69% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | -0.00 | -9.52% |
EVE Health Group Limited Corporate Events
EVE Health Group director boosts stake with on-market share purchase
EVE Health Group Limited operates in the healthcare sector, though the announcement provides limited detail on its specific products or services. The company is listed on the ASX and its securities are actively traded, with directors holding signific...
EVE Health Group links ASX trading spike to former shareholder sell-down
EVE Health Group Limited has responded to an ASX price and volume query, stating it is not aware of any undisclosed information that could explain recent trading in its securities. The company says its understanding is that a shareholder formerly ass...
EVE Health Director Updates ASX on Lapse of Performance-Based Options
EVE Health Group Limited has reported a change in the security holdings of director Stuart Gunzburg, detailing adjustments to both his direct and indirect interests in the company. The disclosure notes that Gunzburg maintains significant ordinary sha...
EVE Health Group Trims Future Dilution as 1.0m Options Lapse
EVE Health Group Limited has disclosed a change in its issued capital, notifying the cessation of a series of options listed on the ASX. The options, trading under the code EVEAI and exercisable at $0.06 by December 31, 2028, relate to the company...
EVE Health Sets November 2026 AGM as It Advances Vertically Integrated Pharma Platform
EVE Health Group Limited, an Australian life sciences company, develops and commercialises pharmaceutical products targeting high-growth therapeutic areas such as women’s reproductive health and men’s sexual health. Its lead assets, Dyspr...
EVE Health Group Targets Growth in Reformulated Generic Medicines
EVE Health Group has outlined its strategy to build a commercial-stage pharmaceutical reformulation business targeting established generic medicines that are hard to swallow, inconsistently effective or burdensome in combination therapy. By focusing...
EVE Health Group to Release 2.25 Million Shares from Escrow
EVE Health Group Limited has notified investors that 2,250,000 fully paid ordinary shares will be released from escrow on 9 September 2026 in line with ASX Listing Rule 3.10A. The shares were originally issued in May 2026 as consideration under a cor...
EVE Health Group files ASX governance key for FY2026
EVE Health Group Limited has lodged its annual Appendix 4G with the ASX, detailing how it complies with the ASX Corporate Governance Council’s principles and recommendations. The company’s corporate governance statement for the year ended...
EVE Health Group Posts Wider Loss as Revenue Slides in 2026
EVE Health Group reported a sharp deterioration in financial performance for the year ended 30 June 2026, with revenue from ordinary activities falling 33.53% to $1.15 million compared with the prior year. The loss after tax from continuing operation...
EVE Health Advances Libbo Clinical Program and Hits Apixaban Milestone Amid CEO Transition
EVE Health Group reported progress on its Libbo erectile dysfunction program, finalising the pilot clinical study protocol and engaging a contract research organisation and clinical site to compare its vardenafil oral soluble film with an approved re...
EVE Health advances Libbo clinical program and apixaban reformulation as new CEO targets commercial growth
EVE Health Group has advanced its clinical and technology pipeline in the June quarter, finalising the protocol and engaging a contract research organisation and clinical site for the Libbo pilot study, which will compare its vardenafil oral soluble...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026